These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8522818)

  • 21. Economic and policy implications of reimportation: a Canadian perspective.
    Ward C
    Manag Care; 2004 Mar; 13(3 Suppl):17-20. PubMed ID: 15074165
    [No Abstract]   [Full Text] [Related]  

  • 22. Realizing two-tiered innovation policy through drug regulation.
    Ridgway WE
    Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
    [No Abstract]   [Full Text] [Related]  

  • 23. [Drug legislation 1976: cost analysis for the pharmaceutical industry].
    Kopf R
    Internist (Berl); 1980 Jun; 21(6):333-8. PubMed ID: 7005170
    [No Abstract]   [Full Text] [Related]  

  • 24. Direct-to-consumer advertising--where does the public interest lie?
    Saunders B
    N Z Med J; 2003 Aug; 116(1180):U557; discussion U557. PubMed ID: 14581978
    [No Abstract]   [Full Text] [Related]  

  • 25. Cost-effectiveness data on biologics needed.
    Sheridan C; Katsnelson A
    Nat Biotechnol; 2005 Mar; 23(3):272-3. PubMed ID: 15765069
    [No Abstract]   [Full Text] [Related]  

  • 26. Deals landscape: notable deals in the pharmaceutical industry in the second quarter of 2008.
    Bright J; Lakeram M
    IDrugs; 2008 Aug; 11(8):584-91. PubMed ID: 18724496
    [No Abstract]   [Full Text] [Related]  

  • 27. Italian health sector in disarray following more scandals.
    Abbott A
    Nature; 1993 Aug; 364(6439):663. PubMed ID: 8355773
    [No Abstract]   [Full Text] [Related]  

  • 28. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Policy implications of drug importation.
    Palumbo FB; Mullins CD; Slagle AF; Rizer J
    Clin Ther; 2007 Dec; 29(12):2758-67. PubMed ID: 18201594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Health Canada wants more funds from pharma.
    Vogel L
    CMAJ; 2017 Jun; 189(24):E845-E846. PubMed ID: 28630367
    [No Abstract]   [Full Text] [Related]  

  • 31. [Drug National Policy].
    Rev Saude Publica; 2000 Apr; 34(2):206-9. PubMed ID: 10881160
    [No Abstract]   [Full Text] [Related]  

  • 32. Funding pharmaceutical innovation through direct tax credits.
    Lybecker KM; Freeman RA
    Health Econ Policy Law; 2007 Jul; 2(Pt 3):267-84. PubMed ID: 18634650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Critical analysis of drug policy in Brazil].
    Zepeda Bermúdez JA; de Albuquerque Possas C
    Bol Oficina Sanit Panam; 1995 Sep; 119(3):270-7. PubMed ID: 7576188
    [No Abstract]   [Full Text] [Related]  

  • 34. Generic drugs: cutting cost, not corners.
    Rados B
    FDA Consum; 1985 Oct; 19(8):26, 28-9. PubMed ID: 10311663
    [No Abstract]   [Full Text] [Related]  

  • 35. Hospital pharmacists seek to control sales rep activities.
    Alt SJ
    Hosp Mater Manage; 1992 Apr; 17(4):2, 16. PubMed ID: 10170987
    [No Abstract]   [Full Text] [Related]  

  • 36. Adopting orphan drugs: Congress tries to encourage new remedies for rare diseases.
    Wallis C
    Time; 1982 Oct; 120(15):76, 79. PubMed ID: 10317248
    [No Abstract]   [Full Text] [Related]  

  • 37. Clean drugs for Italy?
    Nature; 1993 Aug; 364(6439):658. PubMed ID: 8355770
    [No Abstract]   [Full Text] [Related]  

  • 38. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects].
    Stargardt T; Schreyögg J; Busse R
    Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Organic synthesis remains relevant in drug discovery.
    Mehrotra MM
    Nature; 2007 Oct; 449(7162):535. PubMed ID: 17914370
    [No Abstract]   [Full Text] [Related]  

  • 40. Industry-to-physician marketing and the cost of prescription drugs.
    Chiong W
    Am J Bioeth; 2003; 3(3):W28-W29. PubMed ID: 14594480
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.